Anti-IL22 Recombinant Antibody (Fezakinumab) (CAT#: TAB-748)

Recombinant human monoclonal antibody expressed in CHO binding to human IL22. Fezakinumab is a human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
SDS-PAGE

Figure 1 Anti-IL22 Recombinant Antibody (TAB-748) in SDS-PAGE

Figure 1 Anti-IL22 Recombinant Antibody (TAB-748) in SDS-PAGE

Lane 1: Reduced
Lane 2: Non-reduced

SEC-HPLC

Figure 2 Anti-IL22 Recombinant Antibody (TAB-748) in HPLC

Figure 2 Anti-IL22 Recombinant Antibody (TAB-748) in HPLC

The purity of TAB-748 was greater than 95% as determined by SEC-HPLC.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - lambda
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in IF, IP, Neut, FuncS, ELISA, FC, IHC and most other immunological methods.
  • CAS
  • 1007106-86-6
  • Generic Name
  • fezakinumab
  • UNII
  • 0S77U25XZ3
  • MW
  • 143.87 kDa
  • Related Disease
  • Inflammatory conditions, acute and chronic

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Target

  • Alternative Names
  • fezakinumab;1007106-86-6;ILV-094;IL22;interleukin 22;interleukin-22;IL 10 related T cell derived inducible factor;IL 21;IL 22;IL D110;IL TIF;ILTIF;MGC79382;MGC79384;TIFa;TIFIL 23;zcyto18;cytokine Zcyto18;IL-10-related T-cell-derived inducible factor;IL-10

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Fezakinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Fezakinumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Fezakinumab"

Afuco™ Anti-IL22 ADCC Recombinant Antibody (Fezakinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human IL22. Fezakinumab is a human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis.

See other products for "IL22"

Single-domain Antibody

CAT Product Name Application Type
NAB-1442-sdAb Recombinant Anti-Human IL22 VHH Single Domain Antibody WB, ICC, ChiP, FA, ELISA Llama VHH

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-748 Afuco™ Anti-IL22 ADCC Recombinant Antibody (Fezakinumab), ADCC Enhanced IP, IF, FuncS, FC, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-748. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare